Open Data Infrastructure
Open Data Infrastructure for Pharma and Life Sciences
Why GxP data integrity, audit trails, and long retention make open data infrastructure a better default for pharma and life sciences data.
In pharma, trust is not a feeling. It is an audit trail. If you cannot reconstruct a result, you do not have data. You have risk.
Why it matters
GxP environments care about data integrity, access control, and reproducibility. That applies to pipelines, exports, and transformations, not only to a single application UI.
Closed platform boundaries can simplify operations, but they can also make it harder to prove portability and long-term defensibility across changing vendors and long retention horizons.
The ODI angle
ODI gives life sciences teams a way to keep analytical data portable while still enforcing strong controls. Open formats and open catalogs make exit paths and interoperability possible without losing the contract.
Guidance like the FDA data integrity Q&A and the UK MHRA guidance highlight the expectations. You still have to implement the controls as system behavior.
Open does not remove validation responsibilities. It makes it possible to evolve the stack without turning every change into a replatforming event.
Core idea: integrity evidence has to survive platform changes, not just platform launches.
The architecture test
For life sciences data leaders, the test is whether results can be reproduced with evidence.
- Design for data integrity and audit trails end to end.
- Encode access controls and roles in the data path.
- Capture lineage for transformations that feed regulated outcomes.
- Use open table formats for long-lived analytical data sets.
- Plan retention and reproducibility as operational requirements.
What breaks first
This breaks when validation is assumed instead of proven across the full data path.
- Data integrity is assumed because a platform is validated, but pipelines and exports are not.
- Audit trails exist in one tool but not across the end-to-end flow.
- Long-term retention becomes a platform migration nightmare.
- Governance is treated as documentation instead of enforceable controls.
Questions to ask
Use these questions when you evaluate open data infrastructure pharma in regulated environments.
- Can you reconstruct a result with the exact source data and transformation versions?
- Where are audit trails stored, and can you keep them across platform changes?
- Which controls are automated and which are manual?
- How do you handle vendor exit while preserving validation evidence?
- Can you enforce least-privilege access for analysts, scientists, and agents?
If you cannot answer those questions with evidence, you are depending on hope as your compliance strategy.
Sources to start with
Start with the primary guidance on integrity expectations, then translate those expectations into enforceable architecture.